Results for this period
Interim period (second quarter)2025年1月1日〜2025年6月30日ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
生成AI関連など先端半導体パッケージ基板向け製品の需要が堅調で薬品売上が増加した。人件費等で販売費及び一般管理費が増加したが営業利益は増加し、為替の影響等で経常利益は減少した。補助金収入の計上等により親会社株主に帰属する中間純利益は前年同期比で増加した。
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2025年1月1日〜2025年6月30日 |
| Net Sales | ¥9,387 million (YoY +5.7%) |
| Operating profit | ¥2,440 million (YoY +3.3%) |
| Ordinary income | ¥2,493 million (YoY -5.6%) |
| Profit attributable to owners of the parent | ¥1,893 million (YoY +0.2%) |
| Net income per share | 101.47円 |
| Equity ratio | End of the current fiscal period 83.3 / End of previous period 81.4 |
| Total assets | ¥32,875 million |
| Net assets | ¥27,392 million |
| Cash flows from operating activities | ¥1,120,842 thousand |
| Cash flows from investing activities | ¥-2,234,296 thousand |
| Cash flows from financing activities | ¥-1,338,848 thousand |
| Cash and cash equivalents at end of period | ¥7,791,087 thousand |
| Full-year earnings forecast | Net Sales ¥20,000 million (YoY +9.7%) / Operating profit ¥5,000 million (YoY +9.6%) / Ordinary income ¥5,100 million (YoY +8.9%) / Net income ¥3,600 million (YoY +57.1%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥45 → ¥55(+22.2%) |
| Segment revenue | Japan ¥3,350,839 thousand (YoY -5.5%), Taiwan ¥1,815,230 thousand (YoY +8.4%), Zhuhai (China) ¥1,249,323 thousand (YoY +17.1%), Suzhou (China) ¥1,728,594 thousand (YoY +1.5%), Europe ¥783,015 thousand (YoY +46.9%), Thailand ¥460,041 thousand (YoY +27.7%) |
| Segment profit | Japan ¥1,521,077 thousand (YoY -10.7%), Taiwan ¥211,535 thousand (YoY -14.8%), Zhuhai (China) ¥141,571 thousand (YoY -36.0%), Suzhou (China) ¥189,466 thousand (YoY -38.1%), Europe ¥85,246 thousand (YoY +253.9%), Thailand ¥67,634 thousand (YoY +104.8%) |
| Regional sales | ¥3,350,839 thousand (YoY -5.5%), ¥1,815,230 thousand (YoY +8.4%), ¥1,249,323 thousand (YoY +17.1%), ¥1,728,594 thousand (YoY +1.5%), ¥783,015 thousand (YoY +46.9%), ¥460,041 thousand (YoY +27.7%) |
| Depreciation and amortization | ¥393,929 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥1,673 thousand, Subsidy Income ¥546,447 thousand / Extraordinary loss Loss on sale of fixed assets ¥337 thousand, Loss on Disposal of Fixed Assets ¥148,876 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 20,071,093株 |
| Treasury Shares at Period-End | 1,648,038株 |
| Factors Behind Changes in Business Performance | 生成AI関連など先端半導体パッケージ基板向け製品の需要が堅調で薬品売上が増加した。人件費等で販売費及び一般管理費が増加したが営業利益は増加し、為替の影響等で経常利益は減少した。補助金収入の計上等により親会社株主に帰属する中間純利益は前年同期比で増加した。 |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.生成AI関連など先端半導体パッケージ基板向け製品の需要が堅調に推移したため薬品売上が増加した。販売費及び一般管理費は主に人件費等が増加したが営業利益は増加し、経常利益は為替の影響等で減少した。補助金収入が特別利益に計上されたことなどにより、親会社株主に帰属する中間純利益は前年同期比で増加した。